The new patented tablets consist of both Instant Release and Extended Release formulations with THC and CBD as well as a variety of terpenes and other cannabinoids
Canntab Therapeutics Limited () (OTCQB:CTABF) said Monday it has won a first US patent covering its multi-layer (bi-layer) tablet cannabinoid formulations.
The new patented tablets consist of both Instant Release (IR) and Extended Release (XR) formulations with THC, CBD, and a variety of Terpenes and other Cannabinoids found in full-spectrum Cannabis and Hemp oil resin, the company said.
"This is a major milestone that confirms our proprietary formulations are unique and differentiated from other product offerings in the global marketplace which will support a faster revenue stream as we begin production and distribution in the immediate future,” Canntab CEO Larry Latowsky said in a statement.
READ: Canntab Therapeutics spends C$1.3M on cannabis processing equipment in two all-stock deals
“This is the first patent that was issued to date out of the 13 that we have applied for, and will be leveraged to solidify Canntab's position as the leader in solid dose (hard pill) formulations of medicinal cannabinoids,” Latowsky added.
Canntab said it believes that its hard pill formulations are superior to all other CBD and THC delivery systems since they are true pharmaceutical-grade delivery systems which provide for superior ingredient stability, enhanced bioavailability, and provide customizable and precise dosing.
The company said it intends to prove greater bioavailability through a blood level study at a third party Clinical Research Organization (CRO). In addition, whether it is for medical, recreational or nutraceutical purposes, Canntab said it is able to provide extended-release formulations making it the clear delivery choice for doctors, patients or the average consumer.
"Canntab expects this and future patents to be very valuable in the development of our strategic partnerships and alliances and in our efforts to secure worldwide distribution of our proprietary products,” Latowsky said. “As the medical community continues to recognize Cannabinoid alternatives to traditional therapies, we will continue to develop innovative approaches to support many clinical applications.”
In addition, Canntab said it is conducting research to confirm its belief that its combined CBD and THC tablet can be effective to treat nicotine, alcohol, cannabis, opioid and other forms of addiction.
Clinical trial plan
Canntab said it will be using a derivative of these formulations for its clinical trial with Dr Donald Garbuz from the University of British Columbia. This study aims to demonstrate the potential for the reduction or elimination of the use of opiates in patients during post-operative pain management.
The newly issued patent, which expires on March 15, 2038, covers Canntab's modified release pharmaceutical compositions and more specifically compositions comprising cannabinoids and a process for preparation thereof as well as methods for administering the compositions to human users. The compositions may contain a combination of ingredients in proportions calculated to achieve therapeutic effect.
Canntab has filed applications for 13 patents in Canada and the US that cover a range of processes and formulations that it uses to create its precision oral-delivery hard tablets, the future of medical cannabis.
These patents include Canntab's proprietary nano-emulsification technology, granulation process, methods of manufacturing and covers its full line of precision oral-delivery hard tablets including instant (immediate) release tablets, extended-release tablets, oral dissolvable tablets. Canntab has also filed a patent for an exclusive formulation of THC and CBD for the treatment of opioid addiction treatment therapy.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham